Aetna's CEO said it made no sense to proceed in the "current environment." Federal judges have blocked both the Aetna-Humana merger and a separate deal involving Anthem and Cigna.
Additional reporting by Laura JosztNOTE: This story was updated at 3:40 pm and at 6:02 pm.
Aetna and Humana have called off their planned $37 billion merger, following a federal judge’s ruling to halt the deal.
“While we continue to believe that a combined company would create greater value for healthcare consumers through improved affordability and quality, the current environment makes it too challenging to continue pursuing the transaction,” said Aetna Chairman and CEO Mark T. Bertolini in a statement.
Following the ruling, Humana has decided to exit the Affordable Care Act (ACA)'s insurance exchanges, making it the first major insurer to do so. In a press release, the company stated that it continues to see "signs of an unbalanced risk pool" following 2017's open enrollment period. As such, Humana will exit the ACA exchanges on January 1, 2018. It will continue to serve members across 11 states for the remainder of 2017.
On January 23, 2017, A US District Court granted the US Department of Justice (DOJ) request to block the Aetna-Humana merger on the grounds that it was anticompetitive. In a separate ruling February 9, 2017, a federal judge blocked another large proposed merger between Anthem and Cigna.
In both cases, the DOJ asserted that the mergers would leave some markets with too few choices for consumers seeking health plans.
Under the terms of the original deal, Aetna will pay Humana a $1 billion fee to terminate the deal. Aetna will also halt the sale of some Medicare Advantage assets to Molina Healthcare; this will also require payouts to Molina. The sales were pursued to avoid too much consolidation in certain markets.
Had the 2 mergers gone through, the number of large national payers in the country would have dropped from 5 to 3.
In December, the DOJ criticized Aetna’s behavior when it pointed to internal documents that it said showed Aetna’s decision to withdraw from all but 4 states on the federal exchanges was motivated by the antitrust action, not financial concerns. The federal exchanges sell coverage under the ACA, and 2017 premium increases and a loss of coverage options in many markets were attributed to Aetna’s decision.
Bertolini said during testimony that he expected the merger could have produced $3 billion in efficiencies and savings. The deal would have given the combined company the largest presence in the Medicare Advantage market, which the DOJ said would have resulted in higher premiums for seniors.
On Tuesday, Cigna also announced that it was terminating the proposed merger with Anthem and also filing a lawsuit against Anthem. In addition to the $1.85 billion termination fee that was part of the merger agreement, Cigna is seeking additional damages exceeding $13 billion. According to a statement from Cigna, the damages include the premium Cigna shareholder will not realize as a result of the failed merger.
"Cigna is disappointed in the outcome of this process," the company released in a statement.
After the judge ruled on February 9, Anthem had remained committed to pursuing the merger.
Moving forward, Anthem will continue to work aggressively to complete the transaction..." Anthem President and CEO Joseph R. Swedish had said in a statement the day of the ruling.
"
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More